Swedish skin cancer diagnostic start-up AI Medical Technology has completed the latest stage in its ongoing strategic transformation, appointing two renowned executives to its board.
Stockholm, Sweden, May 14, 2024 – AI Medical Technology, developer of Dermalyser, a smartphone-based tool capable of diagnosing skin cancer with higher sensitivity and specificity than trained dermatologists, has appointed two key new members to its board of directors.The first is Emil Billbäck. As the CEO of the highly successful company BoneSupport, Billbäck has led the company’s rapid commercialization of its pioneering Orthobiologics platform, rendering a share price appreciation of over 800% over the past five years. Speaking on Billbäck’s appointment, Christoffer Ekström, AI